Senior Business Development Manager Job Description

A Senior Business Development Manager in a science-intensive company is part deal-maker, part strategy analyst, and part scientist — depending on the deal under discussion. Their job is to expand the company's value by finding, evaluating, and executing transactions that give the company access to technologies, products, or markets it couldn't reach as efficiently on its own.

In the pharmaceutical and biotech context, that typically means in-licensing clinical-stage assets from smaller biotechs or academic spinouts, negotiating co-development or co-commercialization agreements, managing existing collaboration relationships, and occasionally working on acquisitions. Each of these activities requires a distinct skill set that the Senior BD Manager combines: technical literacy to evaluate whether an asset's clinical data is compelling, financial skills to build a credible NPV model, negotiating skill to reach deal terms that reflect fair value, and project management ability to drive a complex multi-functional process to close.

The deal sourcing work is largely relationship-driven. Senior BD managers build and maintain a network across the industry — scientists and executives at potential partners, venture investors in the relevant space, academic technology transfer offices, and financial advisers who work on transactions. They attend the major partnering conferences — BIO, JP Morgan Healthcare, ASCO, ASH — specifically to maintain existing relationships and develop new ones. The best deals often come from relationships that were built years before the asset was ready to transact.

Deal execution requires coordinating legal, finance, R&D, regulatory, and commercial functions through a process that can run from months for straightforward licenses to years for complex multi-asset collaborations. The BD manager is the orchestrator who keeps that process moving without losing the counterpart's interest or missing the window when terms are most favorable.

Education:

• Advanced degree in a life science or technical field (PhD, MD, PharmD) plus MBA — this is the strongest credential combination for senior pharma/biotech BD roles
• MBA alone from a top-ranked program with 3–5 years in a science or healthcare context
• Some companies value extensive industry experience over specific degree combinations at the senior level

Deal and transaction experience:

• 5–8+ years in pharmaceutical/biotech/medtech BD, investment banking (healthcare focus), or consulting with BD execution experience
• Track record of completed transactions — deals signed and closed, not just evaluated
• Experience with the full deal lifecycle: sourcing, due diligence, term sheet negotiation, definitive agreement, integration or milestone management

Technical and analytical skills:

• Financial modeling: DCF/NPV valuation of drug assets, scenario analysis, milestone and royalty modeling
• Scientific due diligence: ability to critically evaluate Phase I/II clinical data, mechanism of action, competitive positioning
• IP assessment: reading patent landscapes, understanding freedom-to-operate basics (not at attorney level, but enough to engage intelligently)
• Contract basics: term sheet structure, licensing provisions, milestone definitions, change-of-control clauses

Relationship and negotiation skills:

• Active network in the relevant industry sectors — conferences, working groups, professional associations
• Negotiation experience at the term sheet and definitive agreement level
• Cross-functional leadership — running internal deal teams without direct authority over participants

Tools:

• Financial modeling in Excel
• CRM systems for relationship tracking
• Data rooms and M&A due diligence platforms (Intralinks, Ansarada, ShareVault)

Business development roles in science-intensive industries sit at a convergence point between scientific, financial, and commercial skills that is genuinely rare and durably valuable. The supply of people who can credibly evaluate a Phase II asset's clinical data, build a deal model that senior management trusts, and negotiate terms with a sophisticated counterpart is limited — which keeps compensation at the senior level competitive.

The pharmaceutical and biotech transaction market has been consistently active, with licensing deal volume largely tracking R&D investment cycles. Large pharmaceutical companies depend on BD to supplement internal pipelines — the reality of pharmaceutical economics is that no single company can discover enough drugs internally to sustain its commercial operations. That structural dependence on in-licensing and acquisitions ensures that BD organizations at major companies are resourced and valued.

AI-based drug discovery has expanded the universe of potential BD partners and created new transaction structures. Large pharma companies have signed hundreds of AI-platform collaborations in the last several years, and evaluating these opportunities — which require assessing both clinical assets and platform technology quality — is creating new BD skill requirements. Senior managers who develop fluency in evaluating AI-driven discovery platforms have early-mover advantage in a deal type that will be more common going forward.

The medtech and diagnostics sectors have parallel BD functions with similar skill requirements and comparable compensation. Agricultural biotechnology, specialty chemicals, and scientific instrumentation also have BD functions, though typically at lower salary levels than pharmaceutical and biotech.

Career advancement leads to VP of Business Development, Chief Business Officer, or in some cases Chief Executive Officer — the BD track is one of the more credible paths to C-suite roles at smaller biotech companies, where dealmaking is a core CEO function. BD Directors at large pharma earn $200K–$260K with bonus; CBOs at mid-size biotechs can earn comparable amounts with meaningful equity.

Dear Hiring Manager,

I'm applying for the Senior Business Development Manager position at [Company]. I have six years in pharmaceutical business development — two years as an analyst at [Bank/Consulting firm] covering healthcare transactions, and the past four years in BD at [Company], where I've been involved in seven completed transactions including three in-licensing deals, one co-development agreement, and three research collaboration agreements.

The deal I'm most proud of was an in-licensing transaction for a Phase II bispecific antibody in [therapeutic area]. I identified the asset through a conference relationship I'd been developing with the company's CMO for two years, led the scientific due diligence with our clinical and regulatory teams, built the deal model under several development and commercial scenarios, and negotiated the term sheet through four rounds. The deal closed at terms that reflected the asset's genuine value without overpaying — the head of R&D specifically commented that the due diligence package I put together was the most rigorous she'd seen on an externally sourced asset.

I've built a meaningful network in the [therapeutic area] space through consistent conference engagement and follow-through on relationships. Several of our recent deal opportunities came through contacts I'd been cultivating for 18 months or more before the asset was ready to transact.

I'm interested in [Company] because of your stated strategic focus on [therapeutic area or technology platform], which aligns with the relationships and market knowledge I've built. I'd welcome the chance to discuss how my background fits.

[Your Name]